Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs

Journal of Alzheimer's Disease : JAD
Erik PorteliusKaj Blennow

Abstract

Alzheimer's disease (AD) is associated with deposition of amyloid-β (Aβ) in the brain, which is reflected by low concentration of the Aβ(1-42) peptide in the cerebrospinal fluid (CSF). The γ-secretase inhibitor LY450139 (semagacestat) lowers plasma Aβ(1-40) and Aβ(1-42) in a dose-dependent manner but has no clear effect on the CSF level of these isoforms. Less is known about the potent γ-secretase modulator E2012. Using targeted proteomics techniques, we recently identified several shorter Aβ isoforms in CSF, such as Aβ(1-16), which is produced by a novel pathway. In a Phase II clinical trial on AD patients, Aβ(1-14), Aβ(1-15) and Aβ(1-16) increased several-fold during γ-secretase inhibitor treatment. In the present study, 9 dogs were treated with a single dose of the γ-secretase modulator E2012, the γ-secretase inhibitor LY450139, or vehicle with a dosing interval of 1 week. The CSF Aβ isoform pattern was analyzed by immunoprecipitation combined with MALDI-TOF mass spectrometry. We show here that Aβ(1-15) and Aβ(1-16) increase while Aβ(1-34) decreases in response to treatment with the γ-secretase inhibitor LY450139, which is in agreement with previous studies. The isoform Aβ(1-37) was significantly increased in a dose-dependen...Continue Reading

Citations

Sep 8, 2011·The Journal of Biological Chemistry·Amelie EbkeHarald Steiner
Aug 2, 2012·The Journal of Biological Chemistry·Johanna WanngrenHelena Karlström
Feb 12, 2013·The Journal of Biological Chemistry·Nikolay PozdnyakovDouglas S Johnson
Apr 26, 2013·Biochemistry·Christina J CrumpYue-Ming Li
Dec 23, 2015·Alzheimer's Research & Therapy·Simon SjödinErik Portelius
Jan 8, 2015·Frontiers in Cellular Neuroscience·Xian ZhangYun-Wu Zhang
Mar 23, 2017·Cold Spring Harbor Perspectives in Medicine·Douglas S JohnsonPeter H St George-Hyslop
Sep 1, 2012·Metabolic Brain Disease·Niklas MattssonErik Portelius
Dec 12, 2012·Neuromolecular Medicine·Magdalena NutuKaj Blennow
Jul 16, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Simone ListaHarald Hampel
Jan 15, 2011·Expert Opinion on Therapeutic Patents·Martin PetterssonDouglas S Johnson
Jul 24, 2013·Expert Opinion on Therapeutic Patents·Martin PetterssonDouglas S Johnson
Oct 3, 2020·Bioorganic & Medicinal Chemistry·Kevin D RynearsonSteven L Wagner
Apr 7, 2020·Seminars in Cell & Developmental Biology·Pengju NieYue-Ming Li
Jan 17, 2014·Journal of Medicinal Chemistry·Martin PetterssonChristopher J O'Donnell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.